BCX17725

Phase 1Small molecule

BBioCryst Pharmaceuticals

BCX17725 is one of 3 small molecule programs targeting Netherton syndrome. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Netherton SyndromeRecruiting

Netherton SyndromePhase 1

Recruiting

Competition

Competitive Landscape

3 competitors in Netherton Syndrome

#DrugCompanyPhaseTrials

Elidel

BBausch Health Americas, Inc.

Approved

—2

Stool Collect

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 3

BCX17725

BBioCryst Pharmaceuticals

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Netherton Syndrome

NCT06539507

Clinical

Trials by Indication[1]

Netherton syndrome1 trial

A Phase 1/1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of BCX17725 in Healthy Participants and Multiple Doses of BCX17725 in Participants With Netherton Syndrome

Recruiting·BBioCryst Pharmaceuticals·Phase 1·NCT06539507·78 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BCX17725. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BCX17725 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BCX17725. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BioCryst Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: BBioCryst Pharmaceuticals

BCX17725

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Netherton syndrome1 trial

References

Drug Info

Quick Facts

Related News